FIMAN Awarded "Leading Enterprise in Medical Aesthetic Injectables and Materials" at C-Beauty

On March 26, the 4th C-Beauty China Medical Aesthetics Industry Chain Forum grandly opened at the Hilton Shanghai Hongqiao. FIMAN was honored with the China Medical Aesthetics Industry Chain Award · Leading Enterprise in Medical Aesthetic Injectables and Materials for its outstanding performance across core dimensions including R&D strength, commercialization layout, revenue scale, and industry capital recognition, demonstrating the style and responsibility of an industry leader with solid capabilities.

Under the theme of Beauty Empowered by Scientific and Technological Innovation, this year’s C-Beauty Forum has built a comprehensive exchange ecosystem for the medical aesthetics industry chain covering policy interpretation, technological innovation, clinical application, and industrial collaboration. As the first B2B industry event in China focusing on full-chain collaboration in medical aesthetics, it has established an authoritative platform for dialogue and value symbiosis to drive high-quality industrial development.

During the forum, Ms. Zhao Qing, Director and Deputy General Manager of FIMAN, was invited to attend the sub-forum Innovation and Compliance in Injectable Aesthetics and Regenerative Materials. She delivered an in-depth presentation titled The Scientific Code of FIMAN Active Collagen, comprehensively decoding the scientific research heritage behind the world-class quality collagen, and showcasing the robust technological potential and aesthetic leadership of China’s active collagen industry to peers.

"Consumer aesthetics has awakened. We have moved from the past filler era to the future collagen era, with a growing pursuit of natural-looking results and long-term safety. FILLDERM is a model product in line with this trend — it is not merely a volume filler, but an anti-aging nutrient that enables immediate in-situ supplementation and long-term nutritional regeneration. With China’s collagen power, we are leading a new aesthetic trend for the future," said Zhao Qing.

As a pioneer in China’s active collagen sector, FIMAN will continue to uphold quality, long-term efficacy, and safety, further deepen process innovation and technological breakthroughs, and unleash the infinite potential of technology in empowering beauty. Meanwhile, the company will actively fulfill its social responsibilities by engaging in public welfare initiatives, building a sound industrial ecosystem, and supporting talent development. As an industry leader, FIMAN is committed to steering China’s medical aesthetics industry toward a more regulated, safer, and sustainable high-quality future.